Adherence to Osteoporosis Treatments: Room for Improvement

Overview

Journal Curr Opin Rheumatol

Specialty Rheumatology

Date 2009 May 5

PMID 19412103

Citations 26

Authors

Amy H Warriner

Jeffrey R Curtis

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Osteoporosis is a growing problem worldwide, with the greatest burden resulting from fractures. Currently available are several treatment options that are effective in reducing fracture risk. Patient adherence to these medications is required for benefit to be seen. Yet, similar to other chronic asymptomatic diseases, adherence to osteoporosis therapies is poor. The reasons for suboptimal adherence are multiple but include fear of possible side effects, dosing requirements, and an unwillingness to take a medication for a 'silent' disease. Poor adherence leads to reduced effectiveness, increased morbidity, and increased medical costs.

Recent Findings: Efforts to improve adherence to osteoporosis treatments are ongoing. The first obstacle in improving adherence to osteoporosis treatments is determining causes of poor adherence. Despite several identifiable causes, improving adherence is difficult. Passive patient education with printed information alone does not appear very effective. Physician-patient interaction, including discussion of bone mineral density results, discussion of osteoporosis medication benefits, and feedback of treatment effects, may be more effective.

Summary: Improved patient education, better tolerated and less frequently dosed medications, and more healthcare provider-patient interaction may improve adherence and lead to greater fracture reduction.

Citing Articles

Impact of Medication Adherence on Bone Mineral Density and Fracture Risk in Patients With Osteoporosis: A Systematic Review.

Alahmari M, AlHilali A, Thabet T, Alshahrani M, Mobasher W, Al Mubarak D Cureus. 2023; 15(7):e42115.

PMID: 37602050 PMC: 10436998. DOI: 10.7759/cureus.42115.

Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis.

Singer A, McClung M, Tran O, Morrow C, Goldstein S, Kagan R Arch Osteoporos. 2023; 18(1):42.

PMID: 36905559 PMC: 10008255. DOI: 10.1007/s11657-023-01229-7.

Factors affecting the changes in antihypertensive medications in patients with hypertension.

Chung T, Jeon Y, Hong Y, Hong S, Moon J, Lee H Front Cardiovasc Med. 2022; 9:999548.

PMID: 36247446 PMC: 9561640. DOI: 10.3389/fcvm.2022.999548.

Multipronged Programmatic Strategy for Preventing Secondary Fracture and Facilitating Functional Recovery in Older Patients after Hip Fractures: Our Experience in Taipei Municipal Wanfang Hospital.

Chen Y, Chang W, Wen T, Chien P, Huang S, Kuo Y Medicina (Kaunas). 2022; 58(7).

PMID: 35888594 PMC: 9315530. DOI: 10.3390/medicina58070875.

Understanding Physicians' Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach.

Qu H, Silverman S, Shewchuk R, Curtis J, Austin S, Greenspan S Risk Manag Healthc Policy. 2022; 15:1293-1302.

PMID: 35818434 PMC: 9270903. DOI: 10.2147/RMHP.S361559.

References

Lau E, Papaioannou A, Dolovich L, Adachi J, Sawka A, Burns S . Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician. 2008; 54(3):394-402. PMC: 2278357. View

Yood R, Emani S, Reed J, Lewis B, Charpentier M, Lydick E . Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003; 14(12):965-8. DOI: 10.1007/s00198-003-1502-4. View

Lo J, Pressman A, Omar M, Ettinger B . Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17(6):922-8. DOI: 10.1007/s00198-006-0085-2. View

Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C . Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2007; 19(6):811-8. DOI: 10.1007/s00198-007-0506-x. View

Delmas P, Vrijens B, Eastell R, Roux C, Pols H, Ringe J . Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007; 92(4):1296-304. DOI: 10.1210/jc.2006-1526. View

Sunyecz J, Mucha L, Baser O, Barr C, Amonkar M . Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008; 19(10):1421-9. DOI: 10.1007/s00198-008-0586-2. View

Clowes J, Peel N, Eastell R . The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004; 89(3):1117-23. DOI: 10.1210/jc.2003-030501. View

Pickney C, Arnason J . Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int. 2005; 16(9):1156-60. DOI: 10.1007/s00198-004-1818-8. View

McHorney C, Schousboe J, Cline R, Weiss T . The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin. 2007; 23(12):3137-52. DOI: 10.1185/030079907X242890. View

10.

Curtis J, Westfall A, Cheng H, Lyles K, Saag K, Delzell E . Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008; 23(9):1435-41. PMC: 2574615. DOI: 10.1359/jbmr.080418. View

11.

Weycker D, Macarios D, Edelsberg J, Oster G . Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006; 17(11):1645-52. DOI: 10.1007/s00198-006-0179-x. View

12.

Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert R . Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82(12):1493-501. DOI: 10.1016/S0025-6196(11)61093-8. View

13.

Lekkerkerker F, Kanis J, Alsayed N, Bouvenot G, Burlet N, Cahall D . Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007; 18(10):1311-7. DOI: 10.1007/s00198-007-0410-4. View

14.

Cooper A, Drake J, Brankin E . Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006; 60(8):896-905. PMC: 1619408. DOI: 10.1111/j.1742-1241.2006.01059.x. View

15.

Lewiecki E, Babbitt A, Piziak V, Ozturk Z, Bone H . Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther. 2008; 30(4):605-21. DOI: 10.1016/j.clinthera.2008.04.009. View

16.

Claxton A, Cramer J, Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310. DOI: 10.1016/s0149-2918(01)80109-0. View

17.

Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R . Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-99. DOI: 10.1056/NEJMoa030897. View

18.

Watts N, Chines A, Olszynski W, McKeever C, McClung M, Zhou X . Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2007; 19(3):365-72. DOI: 10.1007/s00198-007-0460-7. View

19.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

20.

Garber M, Nau D, Erickson S, Aikens J, Lawrence J . The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004; 42(7):649-52. DOI: 10.1097/01.mlr.0000129496.05898.02. View